Displaying drugs 351 - 375 of 537 in total
CIGB 2020 Vaccine
CIGB 2020 is a vaccine candidate administered nasally and sublingually, working to strengthen immunity in the areas administered. The vaccine was developed and tested by the Center for Genetic Engineering and Biotechnology (CIGB), in Havana Cuba. As of July, 2020, a Randomized control clinical trial (RPCEC00000306) is underway to evaluate...
Investigational
PBCAR20A
Investigational
Thallium Tl-201
Thallium Tl-201 is under investigation in clinical trial NCT02697760 (The CZT Dynamic Myocardial Perfusion Imaging).
Investigational
T-2000
T2000 has been used in trials studying the treatment of Myoclonus and Essential Tremor.
Investigational
IO-202
IO-202 is a first-in-class antibody targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) member 4 (LILRB4). It is being investigated in cancers.
Investigational
BN-201
Investigational
TN-201
TN-201 is a gene therapy comprising a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human MYBPC3 gene.
Investigational
Polifeprosan 20
Polifeprosan 20 is under investigation in clinical trial NCT00003878 (Carmustine Implants in Treating Patients With Brain Metastases).
Investigational
Matched Synonyms: … Polifeprosan 20 …
Matched Name: … Polifeprosan 20 …
Matched Description: … Polifeprosan 20 is under investigation in clinical trial NCT00003878 (Carmustine Implants in Treating …
Matched Name: … Polifeprosan 20 …
Matched Description: … Polifeprosan 20 is under investigation in clinical trial NCT00003878 (Carmustine Implants in Treating …
Rubitecan
Investigational
Matched Synonyms: … 9-nitro-20(S)-camptothecin ... 9-nitro-20-(S)-camptothecin …
Matched Iupac: … nitro-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20 …
Matched Iupac: … nitro-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20 …
AUM-601
AUM-601 is a highly selective pan-TRK(tropomyosin receptor kinase). It is currently being investigated in clinical trials for the treatment of cancer.
Investigational
ATX-201
ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic
keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. The Company determined that the program was not meeting their...
Investigational
DTS-201
DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for the treatment of various solid tumors. It is activated in the tumor environment.
DTS-201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and potentially...
Investigational
FAV-201
FAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.
Investigational
ODM-203
Investigational
GL-2045
Investigational
OTL-201
OTL-201 is an investigational hematopoietic stem cell (HSC) gene therapy being developed by Orchard Therapeutics for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA). It consists of a lentiviral vector to insert a functional copy of the human N-Sulfoglucosamine Sulfohydrolase (SGSH) gene into autologous CD34+ hematopoietic stem cells.
Investigational
PYX-201
PYX-201 is an antibody-drug conjugate directed against the extra domain-B splice variant of fibronectin.
Investigational
SIG-205
SIG-205 is a Cultured human retinal pigment epithelial cells (ARPE-19) genetically modified with a non-viral vector to express human native alpha-L-iduronidase enzyme (hIDUA), encapsulated within two-layer modified alginate spheres
Investigational
OTL-203
OTL-203 is an autologous CD34+ enriched cell therapy that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene.
Investigational
EVT 201
EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.
Investigational
DDP-200
DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia.
Investigational
AMG-208
AMG-208 has been used in trials studying the treatment of Cancer, Tumors, Oncology, Prostate Cancer, and Oncology Patients, among others.
Investigational
OCE-205
Investigational
LYT-200
LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9.
Investigational
EDI-200
EDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.
Investigational
Displaying drugs 351 - 375 of 537 in total